Risk Factors for Developing NAION While on GLP-1 Receptor Agonists
The primary risk factors for developing NAION while taking GLP-1 receptor agonists include older age (particularly >50 years), male sex, prolonged diabetes duration, elevated HbA1c, diabetic retinopathy, obesity, cardiovascular disease, pre-existing ophthalmic conditions, and most critically—a crowded "disc-at-risk" optic nerve anatomy 1, 2, 3.
Patient Demographics and Metabolic Factors
The strongest demographic predictor is age over 50 years, with 85.2% of NAION events occurring in this age group among GLP-1 RA users 2. Male sex represents another major risk factor, accounting for 70.3% of cases 2. This gender disparity is consistent across multiple studies examining this association.
Diabetes-Related Risk Factors
Patients with more severe diabetes face elevated risk, specifically those with:
- Prolonged diabetes duration 1
- Elevated HbA1c levels 1
- Diabetic retinopathy 1
- Use of multiple diabetes medications (versus metformin monotherapy) 2
The data shows risk differences were attenuated among metformin monotherapy users (2.0-4.1 per 10,000) compared with users of 2 or more diabetes medications (4.0-5.7 per 10,000) 2. This suggests diabetes severity itself—independent of GLP-1 RA use—contributes substantially to NAION risk.
Cardiovascular and Ophthalmic Risk Factors
Pre-existing cardiovascular disease significantly increases susceptibility 2. Patients with ophthalmic conditions, particularly those with a crowded optic disc (small cup-to-disc ratio), face the highest anatomical risk 3. This "disc-at-risk" configuration is easily detected on routine ocular examination and represents a critical predisposing factor.
Obesity itself is an independent risk factor 1, though the profound metabolic and hemodynamic changes induced by GLP-1 RAs—including rapid weight loss and blood pressure changes—may trigger NAION in anatomically predisposed patients 3.
Medication-Specific Considerations
Semaglutide accounts for 86.5% of reported NAION cases among GLP-1 receptor agonists 1. Risk elevation shows time-dependency, becoming statistically significant after 2 years of exposure 1. Patients who have recently started the medication or increased their dose may face heightened risk during the period of rapid metabolic change 3.
Clinical Context and Absolute Risk
While relative risk increases range from 1.69 to 4.28 across studies 1, 2, 4, 5, absolute risk remains very low—approximately 0.09% in GLP-1 RA users with a risk difference of 0.037% (number needed to harm ~2,700-3,333) 2, 5.
Critical Caveat on Confounding
The observed association may largely reflect confounding by indication rather than direct causation 6. Patients prescribed GLP-1 RAs inherently have more severe diabetes, obesity, and cardiovascular disease—all independent NAION risk factors. Studies using active comparators with similar metabolic profiles (like SGLT-2 inhibitors in patients on metformin) show substantially attenuated or non-significant associations 6, 4.
Risk Stratification for Clinical Practice
Highest risk patients requiring enhanced monitoring:
- Men over 50 years old
- Prolonged diabetes duration with poor glycemic control
- Diabetic retinopathy present
- Cardiovascular disease
- Crowded optic disc on examination
- Multiple diabetes medications
Lower risk patients where standard monitoring suffices:
- Women under 50 years
- Well-controlled diabetes on metformin monotherapy
- No ophthalmic abnormalities
- No cardiovascular disease
The profound cardiovascular, renal, and metabolic benefits of GLP-1 RAs must be weighed against this small absolute increase in NAION risk 6, 5. Routine ophthalmologic screening for disc-at-risk anatomy before initiating therapy in high-risk patients is prudent 3, though no formal guidelines yet mandate this approach.